1. Home
  2. TECH vs IBRX Comparison

TECH vs IBRX Comparison

Compare TECH & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bio-Techne Corp

TECH

Bio-Techne Corp

HOLD

Current Price

$53.50

Market Cap

10.2B

Sector

Health Care

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$6.77

Market Cap

8.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECH
IBRX
Founded
1976
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2B
8.4B
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
TECH
IBRX
Price
$53.50
$6.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
7
Target Price
$71.82
$12.57
AVG Volume (30 Days)
2.0M
22.1M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
0.59%
N/A
EPS Growth
N/A
38.71
EPS
0.49
N/A
Revenue
$1,219,635,000.00
$113,288,000.00
Revenue This Year
$2.49
$88.59
Revenue Next Year
$6.40
$131.15
P/E Ratio
$109.85
N/A
Revenue Growth
5.23
668.31
52 Week Low
$46.02
$1.83
52 Week High
$72.16
$12.43

Technical Indicators

Market Signals
Indicator
TECH
IBRX
Relative Strength Index (RSI) 49.33 43.16
Support Level $49.48 $6.54
Resistance Level $58.88 $8.28
Average True Range (ATR) 1.98 0.88
MACD 0.62 -0.19
Stochastic Oscillator 81.67 9.00

Price Performance

Historical Comparison
TECH
IBRX

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Share on Social Networks: